Literature DB >> 12449498

Assessment of type I error rates for the statistical sub-model in NONMEM.

Ulrika Wählby1, M René Bouw, E Niclas Jonsson, Mats O Karlsson.   

Abstract

The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates.

Entities:  

Mesh:

Year:  2002        PMID: 12449498     DOI: 10.1023/a:1020254823597

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Goodness-of-fit in generalized nonlinear mixed-effects models.

Authors:  E F Vonesh; V M Chinchilli; K Pu
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences.

Authors:  Jogarao V S Gobburu; John Lawrence
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 4.  Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial.

Authors:  E I Ette
Journal:  Ann Pharmacother       Date:  1998 Jul-Aug       Impact factor: 3.154

5.  Population pharmacokinetic modeling: the importance of informative graphics.

Authors:  E I Ette; T M Ludden
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

6.  Variance components testing in the longitudinal mixed effects model.

Authors:  D O Stram; J W Lee
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

7.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 8.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982
  8 in total
  32 in total

1.  Population pharmacokinetics of carbamazepine in elderly patients.

Authors:  Baralee Punyawudho; Eugene R Ramsay; Richard C Brundage; Flavia M Macias; Joseph F Collins; Angela K Birnbaum
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

2.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

3.  Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Authors:  Ulrika Wählby; Katalin Matolcsi; Mats O Karlsson; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

4.  Design of pharmacokinetic studies for latent covariates.

Authors:  Chakradhar V Lagishetty; Carolyn V Coulter; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

5.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

6.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

Review 7.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

8.  A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics.

Authors:  Tze Leung Lai; Mei-Chiung Shih; Samuel P Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-10       Impact factor: 2.745

9.  Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Authors:  Bruce Green; Herta Crauwels; Thomas N Kakuda; Simon Vanveggel; Anne Brochot
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

10.  Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.

Authors:  E Niclas Jonsson; Fiona Macintyre; Ian James; Michael Krams; Scott Marshall
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.